IDRx launches with $122M to develop combo therapy that addresses precision medicine 'whack-a-mole'

Describing a new treatment as “precision medicine” has become so commonplace it feels like the term has blended in with the plethora of pharma jargon that means everything and nothing at the same time. But the founders of IDRx are hoping to jolt meaning back into the modality with specified cancer treatments.